Clinical Trial Update: To Evaluate the Efficacy and Safety of Gefitinib in Adjuvant Chemotherapy for Lung Adenocarcinoma [Phase 3]

View source ↗

Summary

Phase 3 clinical trial evaluating gefitinib as adjuvant therapy after chemotherapy for lung adenocarcinoma (NSCLC) with EGFR mutation.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Gefitinib (Gefitinib)

Snippet

Sponsor: Shenzhen People's Hospital | Conditions: NSCLC, EGFR | Phase 3 | Status: UNKNOWN